NuVasive Stock Forecast, Price & News

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NuVasive in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NuVasive stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NUVA, but not buy additional shares or sell existing shares.
View analyst ratings for NuVasive or view top-rated stocks.

11 brokerages have issued twelve-month target prices for NuVasive's shares. Their NUVA stock forecasts range from $54.00 to $83.00. On average, they expect NuVasive's stock price to reach $63.78 in the next year. This suggests a possible upside of 25.9% from the stock's current price.
View analysts' price targets for NuVasive or view top-rated stocks among Wall Street analysts.

NuVasive's stock was trading at $52.48 at the beginning of 2022. Since then, NUVA stock has decreased by 3.4% and is now trading at $50.67.
View the best growth stocks for 2022 here.

NuVasive is scheduled to release its next quarterly earnings announcement on Wednesday, July 27th 2022.
View our earnings forecast for NuVasive.

NuVasive, Inc. (NASDAQ:NUVA) released its quarterly earnings results on Wednesday, May, 4th. The medical device company reported $0.54 EPS for the quarter, beating analysts' consensus estimates of $0.38 by $0.16. The medical device company had revenue of $290.80 million for the quarter, compared to analyst estimates of $277.63 million. NuVasive had a positive trailing twelve-month return on equity of 11.85% and a negative net margin of 3.23%. The company's quarterly revenue was up 7.2% on a year-over-year basis. During the same quarter last year, the business earned $0.37 EPS.
View NuVasive's earnings history.

NuVasive declared that its board has approved a share buyback plan on Tuesday, November 9th 2021, which permits the company to repurchase $100,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to purchase up to 3.5% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company's management believes its shares are undervalued.

NuVasive updated its FY 2022 earnings guidance on Wednesday, May, 11th. The company provided earnings per share (EPS) guidance of $2.15-$2.45 for the period, compared to the consensus EPS estimate of $2.17. The company issued revenue guidance of $1.21 billion-$1.23 billion, compared to the consensus revenue estimate of $1.21 billion.

59 employees have rated NuVasive CEO Chris Barry on Glassdoor.com. Chris Barry has an approval rating of 88% among NuVasive's employees.

Some companies that are related to NuVasive include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), Boston Scientific (BSX), Baxter International (BAX), ResMed (RMD), DexCom (DXCM), IDEXX Laboratories (IDXX), STERIS (STE), Hologic (HOLX), Insulet (PODD) and Teleflex (TFX).
View all of NUVA's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other NuVasive investors own include BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), Intel (INTC), Alibaba Group (BABA), (MDVN) (MDVN), Micron Technology (MU), Bank of America (BAC), Gilead Sciences (GILD) and Applied Materials (AMAT).

NuVasive trades on the NASDAQ under the ticker symbol "NUVA."

NuVasive's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.70%), Dimensional Fund Advisors LP (2.59%), Paradice Investment Management LLC (2.41%), Goldman Sachs Group Inc. (2.02%), Loomis Sayles & Co. L P (1.46%) and Fisher Asset Management LLC (1.44%). Company insiders that own NuVasive stock include Gregory T Lucier, James Christopher Barry, Lucas Vitale, Massimo Calafiore, Matthew Link and Paul Mcclintock.
View institutional ownership trends for NuVasive.

NUVA stock was sold by a variety of institutional investors in the last quarter, including Pier 88 Investment Partners LLC, Anchor Capital Advisors LLC, Paradice Investment Management LLC, Royal Bank of Canada, The Manufacturers Life Insurance Company , Rothschild & Co. Asset Management US Inc., SG Americas Securities LLC, and Vanguard Group Inc.. Company insiders that have sold NuVasive company stock in the last two years include James Christopher Barry, Lucas Vitale, and Massimo Calafiore.
View insider buying and selling activity for NuVasive or view top insider-selling stocks.

NUVA stock was acquired by a variety of institutional investors in the last quarter, including Polar Asset Management Partners Inc., Nuance Investments LLC, Goldman Sachs Group Inc., Leeward Investments LLC MA, Frontier Capital Management Co. LLC, Woodline Partners LP, New York State Common Retirement Fund, and Canada Pension Plan Investment Board.
View insider buying and selling activity for NuVasive or or view top insider-buying stocks.

Shares of NUVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NUVA stock can currently be purchased for approximately $50.67.

NuVasive (NASDAQ:NUVA) has a market capitalization of $2.64 billion and generates $1.14 billion in revenue each year. The medical device company earns $-64.09 million in net income (profit) each year or ($0.75) on an earnings per share basis.

NuVasive employs 2,900 workers across the globe.

NuVasive was founded in 1997.

NuVasive's mailing address is 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121. The official website for NuVasive is www.nuvasive.com. The medical device company can be reached via phone at (858) 909-1800, via email at [email protected], or via fax at 800-475-9134.